A longitudinal study of quality of life in advanced non-small cell lung cancer: Cancer and Leukemia Group B (CALGB) 8931
- PMID: 9257067
- DOI: 10.1016/0197-2456(96)00116-x
A longitudinal study of quality of life in advanced non-small cell lung cancer: Cancer and Leukemia Group B (CALGB) 8931
Abstract
A quality of life (QOL) endpoint supplemented standard clinical endpoints of survival, tumor response, and toxicity in a double-blind study conducted by the Cancer and Leukemia Group B (CALGB) where 291 patients with advanced non-small cell lung cancer (NSCLC) were randomly assigned to receive cisplatin/vinblastine with either hydrazine sulfate (HS) or placebo. The difficulties associated with the analysis of the longitudinal QOL data, and the contributions that the QOL endpoint made to the understanding of treatment differences, will be the focus of this paper.
Comment in
-
Does assessment of quality of life in comparative cancer trials make a difference? A discussion.Control Clin Trials. 1997 Aug;18(4):306-10. doi: 10.1016/s0197-2456(97)00053-6. Control Clin Trials. 1997. PMID: 9257069
-
Do quality of life assessments make a difference in the evaluation of cancer treatments?Control Clin Trials. 1997 Aug;18(4):311-7. doi: 10.1016/s0197-2456(97)00054-8. Control Clin Trials. 1997. PMID: 9257070
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical